Tumor vascular normalization (TVN) is associated with antitumor therapeutic efficacy in nasopharyngeal carcinoma (NPC). However, the short time window of TVN is the biggest hindrance to its wide clinical application. We investigated whether targeting TGFB can enhance the TVN effect of BEV-induced PDX models of NPC. We constructed mouse subcutaneous PDX models of NPC and classified the mice into four drug treatment groups, including placebo control, galunisertib, bevacizumab (BEV), and galunisertib + BEV. We performed MRI multi-parameter examinations at different time points and evaluated the vascular density, vascular structure, and tumor hypoxia microenvironment by histopathology. The efficacy of chemotherapy and drug delivery was evaluated by administering cisplatin (DDP). We found that combined therapy with galunisertib and BEV significantly delayed tumor growth, enhanced TVN effect, and improved chemotherapy efficacy compared with monotherapy. Mechanistically, galunisertib reversed the EMT process and inhibited the expression of HIF-1α and VEGF by downregulating LAMC2. Correlation analysis of MRI data and pathological indicators showed that there was a good correlation between them. In this study, we described a novel therapeutic strategy to enhance the TVN effect on NPC. Multi-parameter MRI imaging can replace pathological indicators for non-invasive and real-time monitoring of tumor anti-angiogenesis therapeutic response and guide clinical treatment decisions.